Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection

Experimental Parasitology
Nada S DaifallaLashitew Gedamu

Abstract

In this study, we tested the protective efficacy of recombinant Leishmania donovani iron superoxide dismutase B1 (SODB1) against Leishmania major infection in BALB/c mice. Mice were challenged with L. major 3weeks after the second boost immunization with rSODB1 alone or in the presence of adjuvants. Injection of BALB/c mice with rSODB1 alone elicited both humoral and cellular immune responses. Administration of rSODB1 with CpG ODN or GLA-SE (a synthetic toll-like receptor 4 agonist) adjuvant resulted in the induction of anti-SODB1 IgG1, and more importantly of significantly high levels of IgG2a isotype. Immunization of mice with rSODB1 alone or with adjuvant induced the production of IFN-γ by splenocytes in response to stimulation with L. major soluble leishmanial antigens (SLA). Moreover, immunization protocols involving rSODB1 resulted in a significant decrease in IL-10 as compared to controls. The presence of CpG ODN or GLA-SE adjuvant in the immunization protocols resulted in a relative increase in IFN-γ in response to stimulation with rSODB1 in comparison to immunization with rSODB1 alone. Mice immunized with rSODB1 plus CpG ODN or GLA-SE, were able to partially control their Leishmania infections, as indicated by the redu...Continue Reading

References

Jun 21, 1993·Annals of the New York Academy of Sciences·R L Coffman
Jan 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R D Pearson, A Q Sousa
Oct 8, 1999·Lancet·B L Herwaldt
Dec 13, 2000·International Journal for Parasitology·R W Ashford
Apr 9, 2001·Clinical Microbiology Reviews·E Handman
Aug 9, 2001·Transactions of the Royal Society of Tropical Medicine and Hygiene·P Desjeux
Nov 22, 2001·Journal of Endotoxin Research·M Muzio, A Mantovani
Oct 16, 2002·Trends in Microbiology·David H PersingSteven G Reed
Nov 5, 2002·Nature Reviews. Immunology·David Sacks, Nancy Noben-Trauth
Aug 6, 2003·Expert Review of Vaccines·Steven G ReedAntonio Campos-Neto
Sep 23, 2003·Infection and Immunity·Katherine A PlewesLashitew Gedamu
Jan 31, 2004·Seminars in Immunology·Kiyoshi Takeda, Shizuo Akira
Sep 30, 2004·Nature Immunology·Akiko Iwasaki, Ruslan Medzhitov
Oct 16, 2004·Memórias do Instituto Oswaldo Cruz·Philip T LoVerdeRosemary Cook
Mar 9, 2005·The Journal of Experimental Medicine·Suzanne A MilesDavid M Mosser
Jan 19, 2006·Clinical Microbiology Reviews·Simon L CroftAlan H Fairlamb
Nov 30, 2006·Current Opinion in Immunology·Dieter Kabelitz
Feb 6, 2007·Parasitology·L KedzierskiE Handman
Sep 30, 2009·Vaccine·Sylvie BertholetSteven G Reed

❮ Previous
Next ❯

Citations

Feb 24, 2016·Experimental Parasitology·Iluska Martins PinheiroAndré Luis Menezes Carvalho
Apr 22, 2015·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Carlos A Flores-López, Carlos A Machado
Jan 10, 2020·Expert Opinion on Drug Delivery·Anis AskarizadehAli Khamesipour

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.